OncRef

Clinical Trial: NCT03872180

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Emory University
Information Provided By:Emory University
Last Update Posted:2026-10-02

Study Overview

Brief Summary

This phase II trial studies how well bendamustine, obinutuzumab, and venetoclax work in treating patients with mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving bendamustine, obinutuzumab, and venetoclax may work better in treating patients with mantle cell lymphoma.

Official Title

A Phase II Evaluation of Bendamustine, Obinutuzumab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Conditions

CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive

Intervention / Treatment

  • Drug: Bendamustine
  • Biological: Obinutuzumab
  • Drug: Venetoclax

Other Study ID Numbers

  • IRB00102827
  • NCI-2018-00995
  • Winship4363-18
  • ML40204
  • P30CA138292

Start Date (Actual)

2019-04-11

Primary Completion Date (Actual)

2022-06-06

Study Completion Date (Estimated)

2027-07-15

Enrollment (Actual)

23

Study Type

Interventional

Phase

Phase 2